147 related articles for article (PubMed ID: 26910219)
1. Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions.
Liang L; Zheng W; Liu J; Liang SX
Arch Pathol Lab Med; 2016 Feb; 140(2):148-52. PubMed ID: 26910219
[TBL] [Abstract][Full Text] [Related]
2. The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions.
Danialan R; Assaad M; Burghardt J; Newcomb P; Cartun RW; Mandavilli S
Gynecol Oncol; 2013 Aug; 130(2):383-8. PubMed ID: 23618832
[TBL] [Abstract][Full Text] [Related]
3. New developments in endocervical glandular lesions.
McCluggage WG
Histopathology; 2013 Jan; 62(1):138-60. PubMed ID: 23134447
[TBL] [Abstract][Full Text] [Related]
4. PAX8 and PAX2 expression in endocervical adenocarcinoma in situ and high-grade squamous dysplasia.
Shukla A; Thomas D; Roh MH
Int J Gynecol Pathol; 2013 Jan; 32(1):116-21. PubMed ID: 23202787
[TBL] [Abstract][Full Text] [Related]
5. Differential patterns of PAX8, p16, and ER immunostains in mesonephric lesions and adenocarcinomas of the cervix.
Goyal A; Yang B
Int J Gynecol Pathol; 2014 Nov; 33(6):613-9. PubMed ID: 25272301
[TBL] [Abstract][Full Text] [Related]
6. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
Yemelyanova A; Gown AM; Wu LS; Holmes BJ; Ronnett BM; Vang R
Int J Gynecol Pathol; 2014 Sep; 33(5):492-9. PubMed ID: 25083965
[TBL] [Abstract][Full Text] [Related]
7. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.
McCluggage WG; Sumathi VP; McBride HA; Patterson A
Int J Gynecol Pathol; 2002 Jan; 21(1):11-5. PubMed ID: 11781517
[TBL] [Abstract][Full Text] [Related]
8. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
[TBL] [Abstract][Full Text] [Related]
9. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
10. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
11. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
12. ER-positive endocervical adenocarcinoma mimicking endometrioid adenocarcinoma in morphology and immunohistochemical profile: A case report of application of HPV RNAscope detection.
Chen R; Qin P; Luo Q; Yang W; Tan X; Cai T; Jiang Q; Chen H
Medicine (Baltimore); 2021 Apr; 100(13):e24927. PubMed ID: 33787580
[TBL] [Abstract][Full Text] [Related]
13. Tissue-based Immunohistochemical Biomarker Accuracy in the Diagnosis of Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review of the Literature and Meta-Analysis.
Lee S; Rose MS; Sahasrabuddhe VV; Zhao R; Duggan MA
Int J Gynecol Pathol; 2017 Jul; 36(4):310-322. PubMed ID: 27801764
[TBL] [Abstract][Full Text] [Related]
14. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
Kong CS; Beck AH; Longacre TA
Am J Surg Pathol; 2010 Jul; 34(7):915-26. PubMed ID: 20534993
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.
Jones MW; Onisko A; Dabbs DJ; Elishaev E; Chiosea S; Bhargava R
Int J Gynecol Cancer; 2013 Feb; 23(2):380-4. PubMed ID: 23318908
[TBL] [Abstract][Full Text] [Related]
16. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
Rabban JT; McAlhany S; Lerwill MF; Grenert JP; Zaloudek CJ
Am J Surg Pathol; 2010 Feb; 34(2):137-46. PubMed ID: 20061933
[TBL] [Abstract][Full Text] [Related]
17. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.
McCluggage WG; Jenkins D
Int J Gynecol Pathol; 2003 Jul; 22(3):231-5. PubMed ID: 12819388
[TBL] [Abstract][Full Text] [Related]
18. Mesonephric carcinosarcoma involving uterine cervix and vagina: report of 2 cases with immunohistochemical positivity For PAX2, PAX8, and GATA-3.
Roma AA
Int J Gynecol Pathol; 2014 Nov; 33(6):624-9. PubMed ID: 25272303
[TBL] [Abstract][Full Text] [Related]
19. The spectrum of cervical glandular neoplasia and issues in differential diagnosis.
Loureiro J; Oliva E
Arch Pathol Lab Med; 2014 Apr; 138(4):453-83. PubMed ID: 24678677
[TBL] [Abstract][Full Text] [Related]
20. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus.
Park KJ; Kiyokawa T; Soslow RA; Lamb CA; Oliva E; Zivanovic O; Juretzka MM; Pirog EC
Am J Surg Pathol; 2011 May; 35(5):633-46. PubMed ID: 21490443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
